Skip to main content

Table 4 Serum albumin and survival - multiple cancer sites

From: Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature

First author, year of publication, place Year of data collection Study design, Sample size Cancer type Groups being compared RR (95%Cl), p-value Variables adjusted for
Penel N, 2008, USA [82] October 1997 to October 2002 Retrospective consecutive case series, 148 Breast, colon, rectum, head and neck, lung, others >=3.8 g/dL
<3.8 g/dL
Univariate:
Median overall survival (days)
<38 g/l: 91 (1-2421)
>=38 g/l: 363 (296-429), p = 0.00001
Multivariate: 2.51 (1.51-4.18); 0.0001
Primary site, liver metastases, other viscera metastases, BMI, lymphocyte count, granulocyte count
Lam PT, 2007, Hongkong [12] January to December 2002 Prospective cohort, 170 Lung, liver, lower gastrointestinal tract, breast,
gynecological,
haematological,
nasopharyngeal,
prostate, unknown, others
Continuous variable Univariate: 0.94 (0.91-0.96), <0.001
Multivariate: 0.95 (0.92-0.98), 0.001
Demographic data, tumor characteristics, blood parameters, functional status, comorbidities, total symptom score, and psychosocial parameters
Santarpia L, 2006, Italy [83] January 1996 to September 2003 Retrospective, 152 Stomach, ovaries,
colorectal, endometrium,
breast, ileum,
gallbladder,
pancreas, kidney,
skin, prostate, abdominal sarcoma, unknown
Mean (SD)
2.8 +/-0.6 g/dL
3.1+/- 0.5 g/dL
3.3+/- 0.6 g/dL
Survival in days
For 2.8 +/-0.6 g/dL = <30 days
For 3.1+/- 0.5 g/dL = 30-90 days
For 3.3+/- 0.6 g/dL = >90 days
p = 0.001
Age, gender, height, weight, BMI, hemoglobin, lymphocyte count, cholesterol, CHE, KPS score, pain, ascites, vomiting
Pasanisi F, 2001, Italy [84] 1995-1999 Retrospective consecutive case series, 76 Stomach,
colorectal, ovary, others
Mean (SD)
3.13 +/- .51 g/dL
3.57 +/- .43 g/dL
Survival in months
For 3.13 +/- .51 g/dL <= 3 months
For 3.57 +/- .43 g/dL > 3 months
P = 0.002
Age, weight, BMI, hemoglobin, lymphocyte count, cholesterol, pain and ascites
Vigano A, 2000, Canada [85] July 1, 1996, to December 31, 1998 A prospective cohort of 227 consecutive patients Breast,
gastrointestinal,
lung
>=3.5 g/dL
<3.5 g/dL
Univariate: 1.9 (1.4-2.8), <0.01
Multivariate: 7.3 (2.9-18.1)
Lung primary tumor, presence of liver metastases, tumor burden, co morbidity, performance status, weight loss, lymphocyte count, nausea, LDH
Maltoni M, 1997, Italy [86] NA Prospective consecutive case series, 519 Solid tumors excluding renal cancer and hematological cancer Normal: 3.3-5.5 g/dL
Low: 2.7-3.2 g/dL
Very low: <=2.6 g/dL
Univariate: p = 0.0015
Median length of survival (days):
Normal =40.0
low = 29.5
Very low = 24.0 months
Total WBC, neutrophil percentage, lymphocyte percentage, proteinuria, pseudocholinesterase